Jason R. Dinges, PhD, JD
Investment Advisor, Morningside Technology Advisory LLC
Since February 2011, Dr. Dinges has served as an investment advisor at Morningside Technology Advisory LLC. Prior to that, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s Chemical, Biotechnology and Pharmaceutical practice group. Dr. Dinges also serves on the board of directors of various privately held biotechnology companies. Dr. Dinges received his Ph.D. degree in genetics from Iowa State University and a J.D. degree from the University of Iowa College of Law.
Executive Chair, JDRF T1D Fund
Sean Doherty led the design and creation of the JDRF T1D Fund and became the Fund’s first Board Chair in 2015, following more than a decade of service on the New England Chapter’s Board of Directors, including two years as its President. He served on the JDRF International Board and its Executive Committee from 2016 to 2019. Sean recently retired from his role as Managing Director of Bain Capital, LP, a private global investment firm which he joined in 2005 as the firm’s first general counsel. Earlier in his career he worked at Ropes & Gray LLP and was a law clerk to a federal district judge in Boston. Prior to law school, he was a Lieutenant in the U.S. Navy, in which he served on a Middle East Force frigate from 1990-94. Sean received a J.D. magna cum laude from Harvard Law School and a B.A. magna cum laude in Government from Harvard College. He is a member of the board of trustees of Thayer Academy in Braintree, MA.
Peter Gottlieb, MD
Co-founder, Chief Medical Officer
Peter Gottlieb, MD is Professor of Pediatrics and Medicine with tenure at the University of Colorado Health Science Center, and Director of Translational Research Unit at the Barbara Davis Center for Diabetes, and a practicing endocrinologist. Dr. Gottlieb is active in diabetes research, and currently serves as an Investigator for Type 1 Diabetes at Trialnet, Center Director for T1D Trialnet research at the University of Colorado, member of the Gastroparesis Clinical Research Consortium Data Safety Monitoring Board at NIDDK/Johns Hopkins, member of the Steering Committee of the T Cell Workshop at Immunology of Diabetes Society, and member of Viacyte Data Safety and Monitoring Board. He has previously served the Juvenile Diabetes Research Foundation as member and President of Board of Trustees Mountain States Region. Dr. Gottlieb currently serves on the Editorial Board of Diabetes Technology and Therapeutics, the European Journal of Clinical Investigation, and as a reviewer for Current Opinion in Diabetes and Endocrinology, the Journal of Clinical Endocrinology and Metabolism, Diabetes, and Diabetes Care, and has authored or co-authored numerous publications in peer reviewed journals. Dr. Gottlieb earned a BS degree, Cum Laude, from University of Pennsylvania and MD degree from Robert Wood Johnson Medical School.
Orr Land Company
Ed Orr is a 4th generation rancher, entrepreneur, and successful businessman based in Colorado. The reverence of the free enterprise system and capitalism, engrained by his hard-working ranch forefathers, set him on a course at a very young age of creating several business ventures which continue to thrive today. Ed’s personal life experience and knowledge of T1D has spurred his passion to see the prevention and cure of T1D and other autoimmune diseases. Ed’s concern of the effects of the complications of T1D on the growing T1D population has led him to be actively involved and a financial contributor to IMT from its inception as well as a contributor to T1D research at the Barbara Davis Center for Childhood Diabetes for several years. The contribution made by Ed towards the successful commercialization of the IMT technologies in the prevention and cure of autoimmune diseases will be his highest accomplishment.